Синдром раздраженного кишечника

1. El Serag HB, Olden K, Bjorkman D, El Serag HB, et al. Healthrelated quality of life among persons with irritable bowel syndrome: a systematic review. Alimentary Pharmacology and Therapeutics. 2002;16(6):1171–1185.

2. Akehurst RL, Brazier JE, Mathers N, O`Keefe C, Kaltenthaler E, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmaco economics. 2002;20(7):455–462.

3. Ивашкин В.Т., Полуэктова Е.А. Сочетание синдрома функциональной диспепсии и синдрома раздраженного кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2011;4:75–81.

4. Yarandi SS, Christie J. Functional Dyspepsia in Review: Pathophysiology and Challenges in the Diagnosis and Management due to Coexisting Gastro esophageal Reflux Disease and Irritable Bowel Syndrome. Gastroenterol Res Pract. 2013.

5. Lacy BE, Mearin F, Chang L, Chey WD, et al. Bowel disorders. Gastroenterology. 2016;150:1393–1407.

6. Nagasako CK, Garcia Montes C, Silva Lorena SL, Mesquita MA. Irritable bowel syndrome subtypes: Clinical and psychological features, body mass index and comorbidities. Rev Esp Enferm Dig. 2016;108(2):59–64.

7. Cho HS, Park JM, Lim CH, Cho YK, et al. Anxiety, depression and quality of life in patients with irritable bowel syndrome. Gut Liver. 2011;5(1):29–36.

8. Corsetti M, Whorwell PJ. Managing irritable bowel syndrome in primary care. Practitioner. 2015;259(1783):21–4, 2–3.

9. Bharadwaj S, Barber MD, Graff LA, Shen B. Symptomatology of irritable bowel syndrome and inflammatory bowel disease during the menstrual cycle. Gastroenterol Rep (Oxf). 2015;3(3):185–93.

10. Issa B, Morris J, Whorwell PJ. Abdominal distension in health and irritable bowel syndrome: The effect of bladder filling. Neurogastroenterol Motil. 2018;30(11).

11. «Рациональная фармакотерапия заболеваний органов пищеварения». Руководство для практикующих врачей. под общей ред. В.Т.Ивашкина. Москва. «Издательство Литерра». 2003; c.523-524.

12. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol. 2002;97(11):2812–2819.

13. Menees ST, Kurlander J, Goel A, et al. Meta-analysis of the utility of common serum and fecal biomarkers in adults with IBS. Gastroenterology. 2014;146(Suppl):S194.

14. Menees SB, Powell C, Kurlander J, et al. A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS. Am J Gastroenterol. 2015;110(3):444–454.

15. Irvine AJ, Chey WD, Ford AC. Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Metaanalysis. Am J Gastroenterol. 2016;112(1):65–76.

16. Koh SJ, Lee DH, Lee SH, et al. Incidence and Risk Factors of Irritable Bowel Syndrome in Community Subjects with Culture-proven Bacterial Gastroenteritis. Korean J Gastroenterol. 2012;60(1):13–18.

17. Longstreth GF, Chen Q, Wong C, Yao JF. Increased Systemic Antibiotic Use and Clostridium difficile Infection Among Outpatients With Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2018;16(6):974–976.

18. Ford AC, Spiegel BR, Talley NJ, Moayyedi P. Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279–1286.

19. Кучумова С.Ю. Патогенетическое и клиническое значение кишечной микрофлоры у больных с синдромом раздраженного кишечника. Диссертация на соискание ученой степени кандидата медицинских наук. Москва, 2016 г.

20. de Bortoli N, Tolone S, Frazzoni M, et al. Gastro esophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol. 2018;31(6):639–648.

21. Chey WD, Nojkov B, Rubenstein JH, et al. The Yield of Colonoscopy in Patients With Non-Constipated Irritable Bowel Syndrome: Results From a Prospective, Controlled US Trial. Am J Gastroenterol. 2010;105(4):859–865.

22. Patel P, Bercik P, Morgan DG, et al. Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol. 2015;50(7):816–823.

23. Yang J-F, Fox M, Chu H, Zheng X, et al. Four-sample lactose hydrogen breath test for diagnosis of lactose malabsorption in irritable bowel syndrome patients with diarrhea. World J Gastroenterol. 2015;21(24):7563–7570.

24. Leeds JS, Hopper AD, Sidhu R, Simmonette A, et al. Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. Clin Gastroenterol Hepatol. 2010;8(5):433–8.

25. Guagnozzi D, Arias Á, Lucendo AJ. Systematic review with metaanalysis: diagnostic overlap of microscopic colitis and functional bowel disorders. Aliment Pharmacol Ther. 2016.

26. Ивашкин В.Т., Шептулин А.А., Шифрин О.С., Галимова С.Ф., и соавт. Микроскопический колит: клинические формы, диагностика, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006;16(6):56–60.

27. Chachu KA, Osterman MT. How to Diagnose and Treat IBD Mimics in the Refractory IBD Patient Who Does Not Have IBD. Inflamm Bowel Dis. 2016;22(5):1262–74.

28. Longstreth GF, Tieu RS. Clinically Diagnosed Acute Diverticulitis in Outpatients: Misdiagnosis in Patients with Irritable Bowel Syndrome. Dig Dis Sci. 2016;61(2):578–88.

29. Cuomo R, Barbara G, Andreozzi P et al. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. Eur J Clin Invest. 2013;43(11):1147–55.

30. Wu CY, Chang WP, Chang YH, Li CP, et al. The risk of irritable bowel syndrome in patients with endometriosis during a 5-year follow-up: a nationwide population-based cohort study. Int J Colorectal Dis. 2015;30(7):907–12.

31. Mathur R, Ko A, Hwang LJ, Low K, et al. Polycystic ovary syndrome is associated with an increased prevalence of irritable bowel syndrome. Dig Dis Sci. 2010;55(4):1085–9.

32. Layer P, Andresen V, Pehl C, et al. Guideline Irritable Bowel Syndrome: Definition, Pathophysiology, Diagnosis and Therapy. Joint Guideline of the German Society for Digestive and Metabolic Diseases (DGVS) and the German Society for Neurogastroenterology and Motility (DGNM). Z Gastroenterol. 2011;49:237–93.

33. Moayyedi P, Quigley EM, Lacy BE, et al. The effect of dietary intervention on irritable bowel syndrome: a systematic review. Clin Transl Gastroenterol. 2015:e107.

34. Usai-Satta P, Bellini M, Lai M, Oppia F, et al. Therapeutic Approach for Irritable Bowel Syndrome: Old and New Strategies. Curr Clin Pharmacol. 2018;13(3):164–172;

35. Paduano D, Cingolani A, Tanda E and Usai P. Effect of Three Diets (Low-FODMAP, Gluten-free and Balanced) on Irritable Bowel Syndrome Symptoms and Health-Related Quality of Life. Nutrients. 2019;11:1566

36. Johannesson E, Ringström G, Abrahamsson H, Sadik R. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol. 2015;21(2):600–8.

37. Tuck CJ, Taylor KM, Gibson PR, et al. Increasing symptoms in irritable bowel symptoms with ingestion of galacto-oligosaccharides are mitigated by α-galactosidase treatment. Am J Gastroenterol. 2018;113(1):124–134.

38. Ruepert et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. The Cochrane Collaboration. The Cochrane Library. 2013; Issue 3

39. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2-26.

40. Hou X, Chen S, Zhang Y, Sha W, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783–93.

41. Boisson J, Coudert Ph, Dupuis J, Laverdant Ch, et al. Tolerance de la mebeverine a long terme. Act Ther. 1987;16(4):289–92.

42. Шептулин А.А., Визе-Хрипунова М.А. Сравнительная оценка американских, немецких, французских и российских рекомендаций по ведению больных с синдромом раздраженного кишечника. РЖГГК он-лайн — www.gastro-j.ru.

43. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med. 2000;18;133(2):136–47.

44. Chang FY, Lu C, Chen CY, Luo JC. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2007;22(12):2266–72.

45. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107(1):28–35.

46. Ивашкин В.Т., Драпкина О.М., Шептулин А.А., Шифрин О.С., и соавт. Сравнительная эффективность композиции Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus и Saccharomyces boulardii в лечении больных с диарейным вариантом синдрома раздраженного кишечника. РЖГГК. 2015;25(2):10.

47. Ивашкин В.Т., Драпкина О.М., Шептулин А.А., Шифрин О.С., и соавт. Сравнительная эффективность композиции Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus и прукалоприда в лечении больных с обстипационным вариантом синдрома раздраженного кишечника. РЖГГК. 2015;25(3):21–32.

48. Ivashkin V, Drapkina O, Poluektova Ye, Kuchumova S, et al. The Effect of a Multi-strain Probiotic on the Symptoms and Small Intestinal Bacterial Overgrowth in Constipation-predominant Irritable Bowel Syndrome: A Randomized, Simple-blind, Placebocontrolled Trial. American Journal of Clinical Medicine Research. 2015;3(2):18–23.

49. Guarner F, Sanders MH. Probiotics and prebiotics. World Gastroenterology Organization Global Guidelines. 2017.

50. Ford AC, Quigley EMM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1547–1561.

51. Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-analysis. Intern Med. 2015;54(3):243–9.

52. Skokovic-Sunjic D. Clinical Guide to Probiotic Supplements Available in Canada: Indications, Dosage Forms, and Clinical Evidence to Date. 2015.

53. Steer T, Carpenter H, Tuohy K, Gibson GR. Perspectives on the role of the human gut microbiota and its modulation by pro- and prebiotics. Nutrition Research Reviews. 2000; V13: 229–54.

54. Urbanska AM, Bhathena J, Martoni C, Prakash S. Estimation of the potential antitumor activity of microencapsulated Lactobacillus acidophilus yogurt formulation in the attenuation of tumor genesis in Apc (Min/+) mice. Dig Dis Sci. 2009;54:264–73.

55. Schindlbeck NE, Müller-Lissner SA. Dietary fiber. Indigestible dietary plant constituents and colon function. Med Monatsschr Pharm. 1988;11(10):331–6.

56. Tack J, Müller-Lissner S, et al. Diagnosis and treatment of chronic constipation — a European perspective. Neurogastroenterol Motil. 2011;23(8):697–710.

57. Ивашкин В.Т., Алексеенко С.А., Колесова Т.А., Корочанская Н.В., и соавт. Резолюция Экспертного совета, посвященного проблемам диагностики и лечения функциональных заболеваний желудочнокишечного тракта. РЖГГК. 2016;26(4):109–110.

58. Miller LE, Tennilä J, Ouwehand AC, et al. Efficacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis. Clin Exp Gastroenterol. 2014;12;7:241–8.

59. Mueller-Lissner S, Kamm MA et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol. 2010;105(4);897-903.

60. Bengtsson M, Ohlsson B. Psychological well-being and symptoms in women with chronic constipation treated with sodium picosulphate. Gastroenterol Nurs. 2005;28(1):3–12.

61. Шептулин А.А. Прукалоприд в лечении хронических запоров функциональной природы. РЖГГиК. 2012;22(1):9–13.

62. Sajid MS, Hebbar M, Baig MK, Li A, et al. Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials. J Neurogastroenterol Motil. 2016.

63. Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997;25(5):225–46.

64. Zhong YQ et al. A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrhea-dominant irritable bowel syndromе. Zhonghua Nei Ke Za Zhi. 2007;46(11):899–902.

65. Ивашкин В.Т., Шептулин А.А., Полуэктова Е.А., Рейхарт Д.В., и соавт. Возможности применения Опросника «7×7» (7 симптомов за 7 дней) для оценки динамики симптомов функциональной диспепсии и синдрома раздраженного кишечника. РЖГГК. 2016;26(3):24.

66. Ивашкин В.Т., Полуэктова Е.А., Рейхарт Д.В., Шептулин А.А., и соавт. Эффективность наиболее часто назначаемых групп препаратов у пациентов с функциональными расстройствами желудочно-кишечного тракта (синдромом функциональной диспепсии и синдромом раздраженного кишечника) (Результаты наблюдательного исследования). РЖГГК. 2016;26(4):7–14.

67. Ottillinger B, Storr M, Malfertheiner P, Allescher HD. STW 5 (Iberogast®) — a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr. 2013;163(3-4):65–72.

68. Шептулин А.А., Кайбышева В.О. Эффективность применения растительного препарата STW 5 в многоцелевой терапии функциональной диспепсии. РЖГГК. 2015;25(5):101–106.

69. Ивашкин В.Т., Маев И.В., Шептулин А.А. и соавт. Резолюция Экспертного совета «Как улучшить результаты лечения больных с функциональной диспепсией и синдромом раздраженного кишечника»? Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;2:101–104.

70. Авалуева Е.Б., Адашева Т.В., Бабаева А.Р., Бурдина Е.Г., и соавт. Эффективность и безопасность применения Колофорта при синдроме раздраженного кишечника: итоги многоцентрового двойного слепого плацебо-контролируемого рандомизированного клинического исследования. Гастроэнтерология. 2014;1:36–43.

71. Маев И.В., Самсонов А.А., Яшина А.В., Казюлин А.Н., и соавт. Клиническая эффективность и безопасность схем лечения синдрома раздраженного кишечника (результаты сравнительного исследования). Consilium medicum. 2016;8(18):19–26.

72. Ivashkin VT, Poluektova EA, Glazunov AB, Putilovskiy MA, Epstein OI. Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: results of the Russian observation retrospective program COMFORT. BMC. Gastoenterology. 2020;20:2.

73. Xie C, Tang Y, Wang Y, Yu T, et al. Efficacy and Safety of Antidepressants for the Treatment of Irritable Bowel Syndrome: A Meta-Analysis. PLoSOne. 2015;10(8):e0127815.eCollection.

74. Bundeff AW, Woodis CB. Selective Serotonin Reuptake Inhibitors for the Treatment of Irritable Bowel Syndrome. The Annals of pharmacotherapy. 2014;48(6):777–84.

75. Osler W. The principles and practice of medicine: designed for the use of practitioners and students of medicine. New York: D Appleton and company. 1892.

76. Creed F. Relationship between IBS and psychiatric disorder. Irritable bowel syndrome (Ed. Camilleri M, Spiller RC). 2002:45–54.

77. Dekel R, Drossman DA, Sperber AD. The use of psychotropic drugs in irritable bowel syndrome. Expert Opin Investig Drugs. 2013;22(3):329–39.

78. Hausteiner-Wiehle C, Henningsen P. Irritable bowel syndrome: Relations with functional, mental, and somatoform disorders. World J Gastroenterol. 2014;20(20):6024–6030.

79. Greenwood-Van Meerveld B, Moloney RD, Johnson AC, Vicario M. Mechanisms of stress-induced visceral pain: implications in irritable bowel syndrome. J Neuroendocrinol. 2016 Aug;28(8). DOI:10.1111/jne.12361

80. Pae CU, Lee SJ, Han C, Patkar AA, et al. Atypical antipsychotics as a possible treatment option for irritable bowel syndrome. Expert Opin Investig Drugs. 2013;22(5):565–72.

81. Annaházi A, Róka R, Rosztóczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(20):6031–43.